SBIR-STTR Award

  1. You are here:    Home
  2. Search Databases
  3. Search SBIR-STTR Awards
  4. SBIR-STTR Award

Development of AS01b Mimics by Replacing QS-21 with a New Saponin Adjuvant
Award last edited on: 4/26/2023

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$600,000
Award Phase
1
Solicitation Topic Code
106
Principal Investigator
Suzanne Michalek

Company Information

Adjuvax LLC

622 Renaissance Drive
Hoover, AL 35226
   (205) 936-0770
   contact@adjuvax.net
   www.adjuvax.net
Location: Single
Congr. District: 06
County: Jefferson

Phase I

Contract Number: 75N93022C00037
Start Date: 8/30/2022    Completed: 8/29/2024
Phase I year
2022
Phase I Amount
$600,000
AS01b (composed of the molecules QS-21 and MPL) is a powerful adjuvant best known for being a component of the FDA-approved Shingrix vaccine. Despite its successful track-record as an effective adjuvant, accessibility to AS01b as an adjuvant for use in novel vaccines is a concern due to the limited nature of the saponin molecule QS-21. The awardee seeks to address this problem by developing a mimic of AS01b by replacing QS-21 with a novel saponin molecule.

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----